diazoxide has been researched along with Tyrosinemias in 2 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
Tyrosinemias: A group of disorders which have in common elevations of tyrosine in the blood and urine secondary to an enzyme deficiency. Type I tyrosinemia features episodic weakness, self-mutilation, hepatic necrosis, renal tubular injury, and seizures and is caused by a deficiency of the enzyme fumarylacetoacetase. Type II tyrosinemia features INTELLECTUAL DISABILITY, painful corneal ulcers, and keratoses of the palms and plantar surfaces and is caused by a deficiency of the enzyme TYROSINE TRANSAMINASE. Type III tyrosinemia features INTELLECTUAL DISABILITY and is caused by a deficiency of the enzyme 4-HYDROXYPHENYLPYRUVATE DIOXYGENASE. (Menkes, Textbook of Child Neurology, 5th ed, pp42-3)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hereditary tyrosinemia (HT1) is a rare metabolic disorder associated with accumulation of toxic metabolites of the tyrosine pathway due to a genetically mediated enzyme defect of fumarylacetoacetate hydrolase." | 5.62 | Neonatal hyperinsulinism in transient and classical forms of tyrosinemia. ( Gujral, J; Romero, CJ; Sethuram, S; Sperling, MA, 2021) |
| "Hereditary tyrosinemia (HT1) is a rare metabolic disorder associated with accumulation of toxic metabolites of the tyrosine pathway due to a genetically mediated enzyme defect of fumarylacetoacetate hydrolase." | 1.62 | Neonatal hyperinsulinism in transient and classical forms of tyrosinemia. ( Gujral, J; Romero, CJ; Sethuram, S; Sperling, MA, 2021) |
| "Treatment with diazoxide and chlorthiazide is highly effective, appears to be safe, and does not need to be continued lifelong." | 1.33 | Hyperinsulinism in tyrosinaemia type I. ( Baumann, U; Green, A; Kelly, DA; McKiernan, PJ; Preece, MA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sethuram, S | 1 |
| Sperling, MA | 1 |
| Gujral, J | 1 |
| Romero, CJ | 1 |
| Baumann, U | 1 |
| Preece, MA | 1 |
| Green, A | 1 |
| Kelly, DA | 1 |
| McKiernan, PJ | 1 |
2 other studies available for diazoxide and Tyrosinemias
| Article | Year |
|---|---|
Neonatal hyperinsulinism in transient and classical forms of tyrosinemia.
Topics: Congenital Hyperinsulinism; Diazoxide; Humans; Hyperinsulinism; Infant; Infant, Newborn; Liver; Tyro | 2021 |
Hyperinsulinism in tyrosinaemia type I.
Topics: Blood Glucose; C-Peptide; Chlorothiazide; Diazoxide; Diuretics; Humans; Hyperinsulinism; Hypoglycemi | 2005 |